Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

iTeos Therapeutics, Inc. - Common Stock (NQ:ITOS)

10.12 +0.01 (+0.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iTeos Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, ZIMV, SPTN on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: iTeos Therapeutics, Inc. (Nasdaq - ITOS), ZimVie Inc. (Nasdaq - ZIMV), PharmChem, Inc. (OTC - PCHM), NV5 Global, Inc. (Nasdaq - NVEE)
From Brodsky & Smith LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, CIO, SNV on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, ZIMV, TASK, OLO on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
ITEOS THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of iTeos Therapeutics, Inc. - ITOS
From Kahn Swick & Foti, LLC
Via Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS and ZIMV on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
ITOS Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of iTeos Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right
From iTeos Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
iTeos Therapeutics To Wind Down Operations, Explores Asset Sale: Retail Believes It’s ‘Worth More Selling It Off’
The company decided to wind down operations as part of a review of strategic alternatives aimed at maximizing shareholder value after its collaboration with GSK plc ended. 
Via Stocktwits
Topics Intellectual Property
These stocks are gapping in today's session
The market is buzzing with gapping stocks on Wednesday. Let's uncover which stocks are experiencing notable gaps during today's session. 
Via Chartmill
Heico, Monro, Abercrombie & Fitch, Joby Aviation And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
iTeos Therapeutics Announces Its Intention to Wind Down Operations
From iTeos Therapeutics Inc.
Via GlobeNewswire
This Wayfair Analyst Turns Bearish; Here Are Top 4 Downgrades For Wednesday
 
Via Benzinga
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday
 
Via Benzinga
iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile
iTeos ends belrestotug program with GSK after Phase 2 trial fails to meet key survival goals; company explores strategic options to boost shareholder value. 
Via Benzinga
iTeos, GSK End Collaboration On Experimental Cancer Therapy Development: But Retail’s Extremely Bullish
The two companies worked together to assess the Belrestotug + Dostarlimab doublet in treating a specific type of lung cancer. 
Via Stocktwits
Topics Government
iTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates
From iTeos Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
iTeos to Present Preclinical Data on Potential Best-In-Class Anti-TREM2 Antibody, EOS-215, and Novel PTPN1/2 Inhibitor at the American Association for Cancer Research Annual Meeting 2025
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Announces 2025 Strategic Priorities and Anticipated Milestones
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos to Participate in Upcoming Investor Conferences
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Reports Third Quarter 2024 Financial Results and Provides Business Updates
From iTeos Therapeutics Inc.
Via GlobeNewswire
iTeos Therapeutics to Highlight Inupadenant Preclinical, Translational, and Phase 2 A2A-005 Clinical Trial Data in 2L NSCLC at ESMO Immuno-Oncology Congress
From iTeos Therapeutics Inc.
Via GlobeNewswire
The One-Minute Market Report - Sunday, Sept. 22
In this brief market report, we will take a look at the various asset classes, sectors, equity categories, exchange-traded funds, and stocks that moved the market higher, as well as the market segments... 
Via Talk Markets
Sky Harbour Group, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.